Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BC
Bicycle Therapeutics plc American Depositary Shares
BCYC
Mkt Cap
$241.4M
Volume
550.62K
Next Earnings
October 29th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BC
BCYC
BC
Bicycle Therapeutics plc American Depositary Shares
BCYC
News
·
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook
Mkt Cap
$252.0M
Volume
550.62K
Next Earnings
October 29th
Chart
Financials
Earnings
News
About
Insider
Filings
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook
The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players including Novartis, Oncopeptides, Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen driving innovation through strategic partnerships and technological advancements in peptide design and linker technologies.
GlobeNewswire Inc. · Apr 21, 2026
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025
Bicycle Toxin Conjugates (BTCs) are emerging as a novel targeted oncology technology, offering innovative peptide-based drug delivery with potential applications in cancer treatment and beyond, with early clinical trials showing promising results.
GlobeNewswire Inc. · Aug 29, 2025
Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director
Maxion Therapeutics appointed Dr. Santiago Arroyo as a Non-Executive Director, bringing extensive clinical development expertise from roles at multiple pharmaceutical and biotech companies.
GlobeNewswire Inc. · Aug 27, 2025
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
The advanced urothelial carcinoma market is witnessing significant growth, driven by an aging population and the rising prevalence of metastatic cases. Advances in immunotherapy and targeted treatments are transforming the treatment landscape, with over 20 key companies developing new therapies.
GlobeNewswire Inc. · Mar 3, 2025
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Zacks Investment Research · Jun 27, 2024
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
Zacks Investment Research · Jun 21, 2024
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Zacks Investment Research · Jun 11, 2024
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
Zacks Investment Research · May 24, 2024
Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet
The consensus price target hints at an 85.5% upside potential for Bicycle Therapeutics (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research · May 24, 2024
Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Ocugen (OCGN) have performed compared to their sector so far this year.
Zacks Investment Research · May 21, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
BC
BCYC
Bicycle Therapeutics plc American Depositary Shares
Buy
Sell
Market
Limit
Soon
BCYC
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any BCYC yet.
Related Tickers
Earnings